Search for companies, drugs, and catalysts
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
Regulatory Approvals
Fasedienol Nasal Spray Phase 3 Results Expected
Fasedienol Nasal Spray • Social Anxiety Disorder (SAD)
Target Indication
Social Anxiety Disorder (SAD)
Clinical Trial
Last updated: 12/4/2025
VTGN
Vistagen Therapeutics, Inc.
